Please wait a minute...
European Journal of Gynaecological Oncology  2019, Vol. 40 Issue (5): 739-743    DOI: 10.12892/ejgo4639.2019
Original Research Previous articles | Next articles
Safety and efficacy of new techniques of radiotherapy in oligometastatic recurrent ovarian cancer patients with BRCA1/2 mutation
G. Scandurra1, *(), S. Gieri2, F. Marletta3, B. Pecorino2, S. Nicolini3, G. L. Banna1, G. Scibilia2, P. Scollo2
1Division of Medical Oncology, Cannizzaro Hospital, Catania, Italy
2Division of Gynecology, Cannizzaro Hospital, Catania, Italy
3Division of Radiotherapy, Cannizzaro Hospital, Catania, Italy
4Medical Physics Unit, Cannizzaro Hospital, Catania, Italy
5Division of Nuclear Medicine, Cannizzaro Hospital, Catania, Italy
Download:  PDF(501KB)  ( 187 ) Full text   ( 3 )
Export:  BibTeX | EndNote (RIS)      
Abstract  

Purpose of investigation: To evaluate the effectiveness and safety of radiotherapy (RT) for patients with recurrent ovarian cancer (ROC). Materials and Methods: Twenty-one patients with localized ovarian cancer relapses were treated with simultaneous-integrated boost intensity-modulated radiation therapy and stereotactic body radiation therapy/volumetric modulated arc therapy. BRCA 1/2 mutation was present in 13 patients (62%). Radiation therapy was directed to pelvic and nodal recurrences. Results: The median time to progression after successive lines gradually decreased. Six months after RT all patients had a complete response assessed by 18F-FDG PET/CT and CT scan; the overall response rate was 100%, including 21 complete remissions. Median progression-free survival (PFS) was 13 (range, 4-36) months for all patients; specifically, for patients with BRCA1/2 mutation was 13 (range, 11-19) months and for wild type patients it was six (range, 4-36) months. Patients who had a BRCA1/2 mutation showed significantly longer PFS than those who had not the mutation (median, 13 vs. 6 months) (p < 0.05). Acute and late gastrointestinal and genitourinary toxicity occurred in seven (33%) patients. Conclusions: Due to the effect on delay of successive treatments with radiation therapy, there will be a risk to chronicize ovarian disease. RT should be considered an alternative to secondary surgery in well-selected patients.

Key words:  BRCA mutation      Radiation therapy      Recurrent ovarian cancer      Progression-free survival     
Published:  10 October 2019     
*Corresponding Author(s):  G. SCANDURRA     E-mail:  giusy.scandurra@gmail.com

Cite this article: 

G. Scandurra, S. Gieri, F. Marletta, B. Pecorino, S. Nicolini, G. L. Banna, G. Scibilia, P. Scollo. Safety and efficacy of new techniques of radiotherapy in oligometastatic recurrent ovarian cancer patients with BRCA1/2 mutation. European Journal of Gynaecological Oncology, 2019, 40(5): 739-743.

URL: 

https://ejgo.imrpress.com/EN/10.12892/ejgo4639.2019     OR     https://ejgo.imrpress.com/EN/Y2019/V40/I5/739

[1] T. Shoji, E. Takatori, M. Kagabu, M. Futagami, Y. Yokoyama, H. Tokunaga, N. Yaegashi, T. Ohta, T. Watanabe, T Sugiyama. Relationship between usefulness of irinotecan and pegylated liposomal doxorubicin therapy and the UGT1A1 genotype in patients with recurrent ovarian cancer (TGCU 104 study)[J]. European Journal of Gynaecological Oncology, 2020, 41(3): 380-385.
[2] Can Fang, Yan Zhao, Kezhen Li, Danhui Weng, Peng Wu, Gang Chen, Ding Ma, Juncheng Wei. Diabetes mellitus and epithelial ovarian cancer in Chinese women: a retrospective cohort study[J]. European Journal of Gynaecological Oncology, 2020, 41(2): 260-264.
[3] H. Imafuku, Y. Ebina, K. Suzuki, S. Wakahashi, Y. Miyahara, K. Yoshida, H. Yamada. Definitive radiotherapy in elderly patients and patients with locally advanced cervical cancer with complications[J]. European Journal of Gynaecological Oncology, 2020, 41(1): 60-64.
[4] J. Markowska, E. Nowak-Markwitz, Z. Kojs, W. Sawicki. Considerations related to radical fimbriectomy as an option in prophylaxis against serous carcinoma development[J]. European Journal of Gynaecological Oncology, 2019, 40(5): 709-710.
[5] Hui-Juan Zhang, Bao-Lin Qu, Ling-Ling Meng, Wei Yu, Lin Ma. Clinical observation of short-term efficacies of different hypofractionated radiation therapies after modified radical mastectomy for breast cancer[J]. European Journal of Gynaecological Oncology, 2018, 39(4): 524-532.
[6] J G. Artioli, J. Wabersich, L. Borgato, G. Azzarello. Why tube fimbria-end is the favorite site of carcinogenesis in hereditary ovarian cancer? A review of literature and our institution experience[J]. European Journal of Gynaecological Oncology, 2018, 39(3): 381-385.
[7] N.R. Williams, A. Kurylcio, M. Jankiewicz, J. Romanek, W. Polkowski, N.V. Michalopoulos, M.R. Keshtgar. Aesthetic outcome after breast conserving surgery and either intraoperative radiotherapy or whole breast external beam radiotherapy for early breast cancer: objective assessment of patients in a randomized controlled trial in Lublin, Poland[J]. European Journal of Gynaecological Oncology, 2017, 38(6): 867-870.
[8] L. Yang, X. Zhang, X. Lv, H. Yu. Intensity modulated radiotherapy and brachytherapy for a cervical cancer after renal transplantation[J]. European Journal of Gynaecological Oncology, 2017, 38(1): 162-165.
[9] A. Nishikawa, H. Hashimoto, M. Takeda, K. Kontani, T. Miyatake, M. Mimura, M. Nagamatsu, T. Yokoi. Retrospective analysis of the survival benefit of chemotherapy for recurrent or advanced epithelial ovarian carcinoma in patients previously treated with paclitaxel plus platinum-based chemotherapy[J]. European Journal of Gynaecological Oncology, 2016, 37(4): 451-454.
[10] H. Yoshida, D. Shintani, Y. Imai, K. Fujiwara. Serous tubal intraepithelial carcinoma arising from the intrauterine portion of the fallopian tube after bilateral salpingo-oophorectomy[J]. European Journal of Gynaecological Oncology, 2016, 37(3): 404-406.
[11] K. Lambers, A. Hasenburg, E. Stickeler, G. Gitsch, A.L. Grosu, K. Henne, J. Farthmann. Customized treatment of recurrent gynaecological cancer - the need for intraoperative radiation therapy[J]. European Journal of Gynaecological Oncology, 2016, 37(1): 48-52.
No Suggested Reading articles found!